BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (November 2013)

23 slides from BioSpecifics Technologies's investor presentation, Nov 19, 2013

  1. Slide 1: Injectable Collagenase Development and Commercialization

    sae IngB¥ators in the development ? & commercialization of “ “INJECTABLE _£ COLLAGENASE BioSpecifics Novenibord6hj TECHNOLOGIES CORP

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements”

  3. Slide 3: Company Overview

    Company Overview BioSpecifics is a profitable, commercial-stage biopharma company developing injectable collagenase marketed as XIAFLEX® (collagenase closti jum histolyticum or CCH) in the US and XIAPEX® (the EU tradename for CCH) for a broad range of indications XIAFLEX Marketed for Dupuytren’s Con

  4. Slide 4: Vast Therapeutic Potential

    Vast Therapeutic Potential CCH provides a first-in-class, minimally invasive nonsurgical treatment option for conditions and diseases caused by collagen accumulation where current treatment options are limited BioSpecifics has documented positive results in multiple potential indications: Dupuytren’

  5. Slide 5: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture Definition & Key Complications XIAFLEX is the First and Only Approved Nonsurgical Treatment XIAFLEX US Market Opportunity Focus on Sales Growth and Commercial Expansion Source: Aualium Pharmaceuticals, inc. Formation of a collagen cord in the hand that causes one

  6. Slide 6: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture sBLA for Label Expansion to be Filed in 1Q14 * Positive top-line data reported from Phase IIIb MULTICORD (Multiple Treatment Investigation of Collagenase Optimizing the Resolution of Dupuytren’s) study Evaluated XIAFLEX for the concurrent treatment of adult Dupuyt

  7. Slide 7: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture Data from Multiple Studies Presented at ASSH Collagenase Optimal Reduction tiene CORDLESS is a five-year observational study designed to assess the rates of CRIA TENS BSD GECUTETEDHT SHEMET BLS ome eel aareemnee ESTEE Evaluation of Success Study progression of dis

  8. Slide 8: Deep Clinical Pipeline

    Deep Clinical Pipeline Du; ren’s puye SBLA filing for label expansion expected in 1Q14 Contracture je! ape - PDUFA action date is December 6, 2013 Disease Frozen Start of later stage trials expected in 4Q13 Shoulder Heuibe Top-line date cted in 4Q13 2 fop-line data expected in Lipoma = ae * CAEN Top

  9. Slide 9: Peyronie's Disease

    CCH for Peyronie’s Disease Upcoming December PDUFA Date Excess of inelastic collagen causing penile curvature deformity, which can ete result in pain with erection, penile shortening, indentations, erectile Definition & ldyefanction and /ondifficilty witli eexucl intercourse =Incevere cases penis Ke

  10. Slide 10: Peyronie's Disease

    CCH for Peyronie’s Disease Current Treatment Options Patients currently choose from four treatment modalities: & & Examples include Invasive Surgical eat . plication, grafting, Procedures prosthesis Surgical Procedures Invasive Non- Surgical Verapamil Injection Procedures Non-Invasive Examples inclu

  11. Slide 11: Peyronie's Disease

    CCH for Peyronie’s Disease Positive Top-line Results from IMPRESS Phase III Trials IMPRESS" | and II clinical trial design — Two randomized (2:1 of 0.58 mg CCH or placebo) double-blind Phase Ill trials in over 800 patients at 64 sites in US and Australia, with 52-week follow up ~ Two co-primary endp

  12. Slide 12: Canine and Human Lipomas

    CCH for Canine and Human Lipomas BioSpecifics-Managed Phase II Programs Encapsulated deposits of benign fatty tumors often detected as bulges under Definition & the skin that occur in both humans and dogs Key Complications The most common benign tumors found in humans and can be a serious health pro

  13. Slide 13: Canine Lipomas

    CCH for Canine Lipomas Chien-804 Placebo-Controlled Phase II Trial BioSpecifics conducting placebo-controlled, randomized Phase II trial for CCH in dogs with benign subcutaneous lipomas 32 dogs randomized, single injection 1:1 CCH to placebo Primary efficacy endpoint: Relative change in lipoma volum

  14. Slide 14: Human Lipomas

    CCH for Human Lipomas Dose Escalation Phase II Clinical Trial = BioSpecifics conducting open label, dose escalation Phase II trial for humans with benign subcutaneous lipomas 14 patients at single center with single injection administered in 4 ascending dosage groups ranging from 0.058 mg to 0.44 mg

  15. Slide 15: Uterine Fibroids

    CCH for Uterine Fibroids Preclinical Studies Ongoing Definition & Key Complications Potential to be Nonsurgical Therapy Option US Market Opportunity Benign tumors with significant co- morbidities, which can include pain, decreased fertility, increased rate of miscarriage, heavy menstrual bleeding an

  16. Slide 16: Frozen Shoulder

    CCH for Frozen Shoulder Initiation of Later Stage Trials Expected in 4Q13 Inflammation and thickening of shoulder Definition & capsule due to collagen accumulation, Key Complications Condition often limits the range of motion of the shoulder No FDA-approved pharmaceutical Potential to be Only therap

  17. Slide 17: Frozen Shoulder — Statistically Significant

    Frozen Shoulder — Statistically Significant CCH Dose Response in Phase Ila Study / \ Both the 0.58 mg(1mL) and 0.58 mg(2mL) babe "Forward Flexion cohort demonstrated statistically significant 50 Reber + Shoulder Abduction improvement over baseline scores vs. the [ 1 Extemal Rotation exercise-only gr

  18. Slide 18: Cellulite

    CCH for Cellulite Top-line Data from Phase Ila Study Expected in 1Q15 Definition Significant Market Opportunity as First Nonsurgical Therapy Top-line Data from Phase Ila Study Expected in 1Q15 Phase Ila Study Based on Phase 1b Trial Source of data: Auxilium Pharmaceuticals, Ine. Skin dimpling as a r

  19. Slide 19: Auxilium Partnership

    Auxilium Partnership BioSpecifics is partnered with Auxilium for the development and commercialization of CCH >$36M Received from Auxilium Future Payments Due to BioSpecifics from Auxilium Royalties from Potential Second Indication Auxilium Opt-In Rights Ex-US Strategic Partnerships Over $36M total

  20. Slide 20: Corporate Highlights

    Corporate Highlights Strong Intellectual Property Portfolio Long-term patent protection for injectable collagenase: * Dupuytren’s contracture: XIAFLEX has Orphan Drug protection in US until 2017; Drug product composition patent until 2028 and Biologic Exclusivity until 2022 Peyronie’s disease: Auxil

  21. Slide 21: Consistently Profitable Annually

    Consistently Profitable Annually 3Q13 Financial Highlights For the quarter For the year ended ended 09/30/13 12/31/12 (unaudited) (unaudited) Cash and equivalents, short term investments S$ 11,333,942 $ 8,503,737 Income Statement Revenues § 3,145,123 $ 11,145,078 Other income 7,134 34,634 Costs and

  22. Slide 22: Anticipated Upcoming Milestones

    Anticipated Upcoming Milestones Significant Momentum in Multiple Indications Upcoming Milestones Dupuytren’s Q Announce XIAFLEX 5-year recurrence data in 4Q13 Contracture Q sBLA filing for XIAFLEX label expansion based on multi-cord trial in 1Q14 Peyronie's =) PDUFA date is December 6, 2013 Disease

  23. Slide 23: Injectable Collagenase Development and Commercialization

    sae IngB¥ators in the development ? & commercialization of “ “INJECTABLE _£ COLLAGENASE B oSpec fics November 2013 TECHNOLOGIES CORP

BioSpecifics Technologies — Investor Presentation (November 2013) on 6ix